慢性阻塞性肺疾病患者血清中肺泡表面活性蛋白D水平变化的研究  

Serum Level of Surfactant Protein D in Patients with Chronic Obstructive Pulmonary Disease

作　　者：孙丽华[1] 谭焰[1] 孙静[1] 

机构地区：[1]南京医科大学附属南京第一医院呼吸科,江苏南京210006

出　　处：《中国呼吸与危重监护杂志》2011年第5期481-483,共3页Chinese Journal of Respiratory and Critical Care Medicine

基　　金：南京市科技发展计划(编号:ykk10103)

摘　　要：目的探讨慢性阻塞性肺疾病(COPD)患者血清中肺泡表面活性蛋白D(SP-D)的水平变化及其临床意义。方法检测29例COPD急性加重期、26例COPD稳定期及19例健康人血清SP-D水平,比较各组间的差异;并采用多元线性回归分析影响SP-D水平可能的因素,探讨SP-D与肺功能之间的相关性。结果 COPD急性加重期患者血清SP-D为(70.6±20.7)ng/mL,较COPD稳定期和健康对照组均显著增加[(47.9±13.3)ng/mL和(31.2±11.4)ng/mL,P<0.01],COPD稳定期患者血清SP-D水平也明显高于健康对照组(P<0.01)。血清中SP-D与吸烟指数、COPD分期呈正相关,与稳定期COPD患者的FEV1%pred呈负相关。结论血清SP-D在COPD的诊断、分级和分期中有一定的应用价值。Objective To investigate the serum level of surfactant protein D（SP-D） in patients with chronic obstructive pulmonary disease（COPD） and its clinical significance.Methods Serum levels of SP-D in patients with acute exacerbations of COPD（n=29）,stable COPD（n=26）,and control subjects（n=19） were measured by ELISA.Multiple regression modeling was performed to determine the independent relationship between SP-D and lung function variables.Results The serum SP-D levels were significantly increased in the patients who experienced an acute exacerbation [（70.6±20.7） ng/mL] compared with the patients with stable COPD and the control subjects [（47.9±13.3） ng/mL and（31.2±11.4） ng/mL]（both P0.01）.The serum SP-D levels in the patients with stable COPD increased significantly than the control subjects（P0.01）.Smoking index and staging of COPD were positively related to SP-D level.Serum SP-D levels were also found to be inversely related to FEV1%pred in stable COPD.Conclusion Serum SP-D may be a potential diagnostic and staging biomarker for COPD.

关 键 词：慢性阻塞性肺疾病 急性加重期 肺泡表面活性蛋白D 血清标记物 

分 类 号：R563.9[医药卫生—呼吸系统]